Clinuvel Pharmaceuticals Limited (CUV.XA)
Cboe AU · AUD
A$7.18 (+2.80%) as of
Key statistics
- P/E (TTM)
- 15.27
- EPS (TTM)
- 0.47
- 52-week range
- 6.65 – 13.46
- Beta
- 0.58
- Revenue (TTM)
- 94.02M
- Profit margin
- 36.07%
- Volume
- 20.43k
About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
- Headquarters
- Melbourne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.